OICR welcomes Ms. Susan Fitzpatrick as the new Chair of the OICR Board of Directors. Fitzpatrick, who has been on OICR’s Board since March, brings extensive experience in Ontario’s healthcare sector to the role, as well as strong track record of organizational leadership. She is currently Head of the Canadian Drug Agency Transition Office at Health Canada developing proposals to establish this agency.
Fitzpatrick previously served as interim CEO of Ontario Health, where she oversaw the establishment of the new agency which combined 20 provincial and regional health agencies with $30 billion in funding and more than 12,000 employees. Fitzpatrick also served as CEO of the Toronto Local Health Integration Network and as Associate Deputy Minister in Ontario’s Ministry Health and Long-Term Care.
“We are excited and proud that Susan is our new Chair. Her incredible leadership, knowledge and experience will assist the Institute in improving outcomes for patients and their families by maximizing our impact on Ontario’s healthcare system,” says Dr. Laszlo Radvanyi, President and Scientific Director, OICR. “On behalf of the entire OICR community I welcome her to this role and thank her for her contributions to our work and improving the lives of cancer patients.”
“This is an exciting new opportunity for me to contribute to Ontario’s cancer system with a dynamic organization that is leading cutting-edge research,” says Fitzpatrick.